Overview of bone marrow response and patient outcomes in the previously untreated AML cohort (n = 26) that received TAG-AZA-VEN. (A) Waterfall plot showing the best bone marrow blast response at any cycle as percentage change from baseline. Not shown are 3 patients who left the study prior to bone marrow assessment and 1 patient with secondary AML after myelofibrosis whose bone marrow was fibrotic and acellular at baseline. Two patients received 7 μg/kg TAG (dose level A), 1 received 9 μg/kg (dose level B), and the remaining 23 received 12 μg/kg (dose level C). Best response is annotated by color, as indicated. TP53 mutant status is annotated with an “M.” (B) Swimmer plot showing events and outcome for each patient over time from treatment start. Best response is annotated by the color of each bar, as in panel A. Circles indicate the time of first achieving CR, CRi, or MLFS, as indicated; cross is the time of allogeneic stem cell transplantation; triangle is the time of progressive disease (PD); square is the time of death. Annotation at the end of the bar is the status at end of study treatment. Patients without PD or death noted remained in remission at the last known follow-up. TP53 mutant status is annotated with an “M” and the number of cycles of treatment received is indicated.